CRISPR Therapeutics AG (CRSP) Current Leases (2019 - 2026)

CRISPR Therapeutics AG (CRSP) has 8 years of Current Leases data on file, last reported at $18.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 6.32% year-over-year to $18.6 million; the trailing twelve-month figure through Mar 2026 stood at $18.6 million (up 6.32% YoY), and the FY2025 full-year result was $18.6 million, up 7.46% from the prior year.
• Current Leases steadied at $18.6 million in Q1 2026, from $18.6 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $18.6 million in Q1 2026 to a low of $8.3 million in Q2 2022.
• A 5-year average of $15.6 million and a median of $16.0 million in 2024 frame the typical range for Current Leases.
• Across the five-year window, Current Leases tumbled 47.92% in 2022 and soared 79.42% in 2023, its largest moves.
• Tracing CRSP's Current Leases over 5 years: stood at $15.8 million in 2022, then retreated by 1.37% to $15.6 million in 2023, then increased by 10.64% to $17.3 million in 2024, then climbed by 7.46% to $18.6 million in 2025, then advanced by 0.18% to $18.6 million in 2026.
• Business Quant data shows CRSP's Current Leases at $18.6 million in Q1 2026, $18.6 million in Q4 2025, and $18.3 million in Q3 2025.